摘要
目的：探讨氯吡格雷对非ST抬高急性冠脉综合征病人是否能抑制动脉粥样硬化炎症反应。方法：急性冠脉综合征病人115例,分为A组(n=58,阿司匹林),B组(n=57,阿司匹林+氯吡格雷),另选C组(n= 30,健康对照)。分别在用药前、用药后7,30 d抽取空腹静脉血,检测高敏C反应蛋白(hs-CRP)和肿瘤坏死因子α(TNF-α)浓度。观察用药后30 d主要不良心脏事件(MACE)的发生情况。结果：用药前A,B两组病人血清hs-CRP,TNF-α浓度明显高于C组。用药后7 d,A和B两组病人血清hs-CRP,TNF-α的浓度降低。用药后30 d,A和B两组病人血清hs-CRP和TNF-α的浓度进一步降低,且B组较A组下降更显著(P＜0.05)。A和B两组MACE发生情况有显著差异(P＜0.05),尤其心绞痛发作B组明显低于A组(P＜0.01)。结论：氯吡格雷治疗可显著减轻动脉炎症反应,抑制动脉粥样硬化的进展,进而改善急性冠脉综合征病人预后。
AIM： To investigate the effects of clopidogrel and aspirin on high sensitive C-reactive protein （hs-CRP） and tumor necrosis factor-alpha （TNF-α） in non-ST-segment elevation acute coronary artery syndromes （NSTEACS） patients. METHODS： One hundred and fifteen patients with NSTEACS were randomly divided into group A （n = 58,treated with aspirin） and group B （n = 57,treated with clopidogrel and aspirin）. Thirty healthy volunteers were treated as normal control group （group C）. The concentrations of hs-CRP and TNF-α were tested before taking medicine,7 days and 30 days after taking medicine respectively. The major adverse cardiovascular events （MACE） were evaluated for 30 days after taking medicine. RESULTS： Before taking medicine, the concentrations of hs-CRP and TNF-α in both group A and group B were significantly higher than those in group C. Seven days after taking medicine,the concentrations of hs-CRP and TNF-α in both group A and group B decreased signifirantly. Thirty days after taking medirine, the ronrentrations of hs-CRP and TNF-α in both group A and group B decreased significantly. Compared with group A, the concentrations of hs-CRP and TNF-alpha in group B decreased signifirantly （P 〈 0.05） 30 days after taking medirine. MACE was significant different between group A and group B. CONCLUSION： Clopidogrel can redure the the development of atherosclerosis. Accordingly, it improves the prognosis of inflammation of arteries and restrain NSTEACS patients
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第6期413-416,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
血小板聚集抑制剂
氧吡格雷
阿司匹林
炎症
C反应蛋白质
肿瘤坏死因子
预后
急烂冠脉综合征
platelet aggregation inhibitors
clopidogrel
aspirin
inflammation
C-reactive protein
tumor necrosis factor
prognosis
acute coronary artery syndrome
